Qu&Co, Janssen Pharmaceuticals to Develop and Test Quantum Computational Methods Pharma R&D

Qu&Co
Qu&Co and Janssen Pharmaceuticals are exploring ways that pharmaceutical researchers can use quantum technology in research and development.

Qu&Co, a European quantum computational software developer and Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, are launching a three-year research collaboration to develop and test novel quantum computational algorithms and software for applications in pharmaceutical research and development, according to a statement from the companies.

Computational chemistry and machine learning techniques have become powerful tools to accelerate pharmaceutical R&D and quantum computing, in-time, promises to bring further enhancements of such techniques and tools. This collaboration with Qu&Co will determine how pharmaceutical R&D could benefit from quantum computing and on what timeframe one could expect to see the earliest benefits.

Vincent Elfving, CTO at Qu&Co, said “Collaborations with deep domain experts in computational chemistry are key for us to understand where the conventional best-in-class computational techniques are struggling, so that we focus our research on those areas where there is a potential promise of industry relevant quantum advantage”

The collaboration will focus on developing quantum computational solutions and testing them on quantum processors. Part of the research will also employ ‘QUBEC’, Qu&Co’s platform for quantum computational chemistry and materials-science, which offers corporate researchers a glimpse of what the future of computational chemistry will look like.

About Qu & Co
Qu&Co is a quantum computational software company founded in 2017 in Amsterdam, the Netherlands. Its software will empower corporate researchers to run complex chemistry and multiphysics simulations on future quantum processors with unprecedented accuracy and speed. Qu&Co’s SaaS quantum solutions, like its chemistry and materials-science platform ‘QUBEC’, include unique and patented quantum algorithms and are distributed as backend integrations to leading conventional software packages. Qu&Co clients include corporate researchers from a range of large multinationals, and it has partnerships with US and European quantum hardware players and R&D collaborations with leading Universities from around the world. For more information visit www.quandco.com.

About Janssen Pharmaceuticals
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at www.janssen.com.




Matt Swayne
Matt Swayne
Matt Swayne is a contributor at The Quantum Daily. He focuses on breaking news about quantum discoveries and quantum computing. Matt enjoys working on -- and with -- startups and is currently working on a media studies master's degree, specializing in science communication.

Related Articles

Jobs Board

TQI jobs board provides exclusive jobs offerings all over the internet from tech, quantum, digital and scientific organisations.

Latest Articles

The Quantum Insider